<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100660">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01695759</url>
  </required_header>
  <id_info>
    <org_study_id>EPOBLA1011</org_study_id>
    <secondary_id>Emenda 01 13/08/2012</secondary_id>
    <nct_id>NCT01695759</nct_id>
  </id_info>
  <brief_title>Evaluation Of Clinical Efficacy And Immunogenicity Of Eritromax® Produced By Lab Blau Pharmaceutical S / A. Compared To The Product Eprex®, Produced By The Laboratory Janssen-Cilag, In Patients With Anemia Secondary To Chronic Kidney Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>L.A.L Clinica Pesquisa e Desenvolvimento Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>L.A.L Clinica Pesquisa e Desenvolvimento Ltda.</source>
  <oversight_info>
    <authority>Brazil: National Health Surveillance Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical efficacy and immunogenicity of the drug test Eritromax ® - (rHuEPO
      Blau) compared to drug Eprex ® (Janssen-Cilag rHuEPO) in the treatment of patients who have
      anemia secondary to chronic kidney disease (CKD), during the correction through assessing
      the change in hemoglobin levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be assessed secondary efficacy of the drug against the test drug comparison by
      evaluating:

        -  Maintenance of hemoglobin levels (baseline vs. end of treatment) during maintenance
           phase;

        -  Dose of EPO necessary during the repair and maintenance;

        -  Need for transfusion;

        -  Safety study drugs by type, frequency and intensity of adverse events during the 12
           months of follow up.

      objectives exploratory

        -  evaluate the immunogenicity of drugs through the quantification of anti-erythropoietin
           every six months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change of serum Hb (baseline vs end of treatment (EOIT)</measure>
    <time_frame>until 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maintenance of Hb levels</measure>
    <time_frame>until the end of 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Epoetin alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epoetin alfa Test - Blau</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eprex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epoetin alfa Comparator - JANSSEN-CILAG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa</intervention_name>
    <description>The drug will be administered subcutaneously and the initial dose is 50 IU / kg. This dose will be administrated twice/week, totaling 100 U / kg / week.</description>
    <arm_group_label>Epoetin alfa</arm_group_label>
    <arm_group_label>Eprex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        a. Confirm voluntary participation and agree to all the purposes of the study by signing
        and dating the IC in two ways; b. Male or female, regardless of race or social class; c.
        Age between 18 and 60 years; d. Bearer dialysis-dependent CKD (hemodialysis and peritoneal
        dialysis *); and. Present clinical diagnosis of anemia, characterized in hemoglobin levels
        &lt;10g/dL before the start of the study; f. Adequate dialysis: Kt / V ≥ 1.2 for hemodialysis
        patients and ≥ 1.8 for patients on peritoneal dialysis (based on the calculation of
        Daugirdas II); g. Display adequate iron stores (TSAT&gt; 20% and serum ferritin&gt; 100ng/ml)
        prior to initiation of treatment with erythropoietin

        Exclusion Criteria:

          1. Participation in clinical trials in the 12 months preceding the survey;

          2. Patients with uncontrolled hypertension, with above average 180/100mmHg and requiring
             hospitalization in the last 6 months;

          3. Presence of other causes of anemia than CRD, such as bleeding, hemolysis, pernicious
             anemia and hemoglobinopathies;

          4. Patients who present changes or clinical abnormalities, qualified as interfering
             changes, such as severe hyperparathyroidism (iPTH&gt; 1000 pg / mL), severe congestive
             heart failure (NYHA Class IV), acute myocardial infarction within the last 3 months,
             or active neoplasia in follow-up, severe liver disease, active infection (leukocyte
             changes), history of aluminum toxicity or scheduled surgery, pregnancy or lactation;
             and. Patients who have a known hypersensitivity to any component of the formulation
             and to products derived from mammalian cells;

        f. Prior therapies with erythropoietin for less than 3 months; g. Realization transfusion
        for less than 3 months; h. Any situation at the discretion of the Principal Investigator
        interfere with study data.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandre Frederico, physician</last_name>
    <phone>(19) 38716399</phone>
    <email>alexandre@lalclinica.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Scribner de Ensino, Pesquisa, Ciência e Tecnologia</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Carlos Riella</last_name>
      <phone>(41) 3027-5442</phone>
      <email>mcriella@pro-renal.org.br</email>
    </contact>
    <investigator>
      <last_name>Miguel Carlos Riella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>União Brasileira de Educação e Assistência Hospital São Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Domingos Otávio Lorenzoni D'Avila</last_name>
      <phone>(51) 3320-3479</phone>
      <email>pesquisanefropucrs@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Domingos Otávio Lorenzoni D'Avila</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>João Carlos Goldani</last_name>
      <phone>(51) 3214-8640</phone>
      <email>ronivantxsantacasa@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>João Carlos Goldani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Ensino Padre Anchieta</name>
      <address>
        <city>São Bernardo do Campo</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>João Batista Douverny, physician</last_name>
      <phone>(11) 4930-4243</phone>
      <email>cemec.abc@terra.com.br</email>
    </contact>
    <investigator>
      <last_name>João Batista Douverny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundação Oswaldo Cruz (Hospital do Rim e Hipertensão)</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Eugênia Canziani</last_name>
      <phone>(11) 5904-8499</phone>
      <email>dialisefor@uol.com.br</email>
    </contact>
    <investigator>
      <last_name>Maria Eugênia Canziani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Real e Benemérita Associação Portuguesa de Beneficência São Paulo (Hospital Beneficência Portuguesa)</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irene de Lourdes Noronha</last_name>
      <phone>(11) 2359-2703</phone>
      <email>irenenor@usp.br</email>
    </contact>
    <investigator>
      <last_name>Irene de Lourdes Noronha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 27, 2012</lastchanged_date>
  <firstreceived_date>September 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia Secondary</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
